SCHEMBL5458428

SCHEMBL5458428

CCOc1ccc(C)cc1NC(=O)Nc1ccc(N2CCNCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.57
SMN1; SMN2 Q16637 7/20 0.57
KMT2A Q03164 6/20 0.57
LMNA P02545 6/20 0.57
MEN1 O00255 5/20 0.57
RAB9A P51151 3/20 0.57
TP53 P04637 2/20 0.57
HTT P42858 1/20 0.57
HRH3 Q9Y5N1 1/20 0.56
NPC1 O15118 3/20 0.50
PKM P14618 2/20 0.50
P2RY1 P47900 1/20 0.49
GAA P10253 3/20 0.48
MAPK1 P28482 2/20 0.48
ALDH1A1 P00352 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
NR4A1 P22736 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5473080 0.89 SMN1; SMN2 (0.55) MAPTSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL5455937 0.89 MAPT (0.52) MAPTSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL5453537 0.88 MAPT (0.63) MAPTSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL5465994 0.87 MAPT (0.56) MAPTSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL5451401 0.86 KMT2A (0.51) MAPTSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL5455863 0.86 KMT2A (0.62) MAPTSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL5473719 0.84 MAPT (0.58) MAPTSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL5463389 0.83 MAPT (0.53) MAPTSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL5458258 0.82 MAPT (0.53) MAPTSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL5465517 0.82 MAPT (0.56) MAPTSMN1; SMN2KMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885SMN1; SMN2 4424/4885KMT2A 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.